There is an increasing need for an animal model that can be used to translate basic research into clinical therapy. We documented the differentiation and functional competence of embryonic stem cell (ESC)-derived endothelial cells in baboons. Baboon angioblasts were sequentially differentiated from embryoid body cultures for 9 days in an angioblast differentiation medium with varying concentrations of BMP-4, FLT-3 ligand, stem cell factor, thrombopoietin, basic fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), and knockout serum replacement. Real-time polymerase chain reaction results showed that ESC-derived angioblasts downregulated NANOG and OCT3/4, upregulated T-brachyury and GATA2, and moderately expressed CD34; they did not express CD144, TEK, or VWF, and varied in levels of CD31 expression. Several populations of putative angioblasts appeared 3 days and 9 days after differentiation, as identified by flow cytometry. Angioblasts at this stage exhibited dual paths of differentiation toward hematopoietic and vascular fates. To examine whether derived angioblasts could reconstitute the endothelium, we built an ex vivo culture system and seeded fluorescently labeled angioblast cultures onto a denuded segment of the femoral artery. We found that the seeded cells were able to grow into the endothelium on the interior surface of denuded artery segments within 5 days after seeding. After 14 days of ex vivo culture, the transplanted cells expressed CD31, an endothelial marker. The control arteries, seeded with vehicle only, did not harbor cells with endothelial markers. We conclude that ESCderived angioblasts are promising therapeutic agents for repairing damaged vasculature, and that the baboon model will be vital for optimizing therapies for human clinical studies.
Introduction
T he endothelium contributes considerably to the pathogenesis of cardiovascular disease (CVD). It is progressively impaired with age, and the supply of tissue reparative cells at an advanced age is insufficient to repair the damage [1, 2] . Although therapeutic developments have improved the prognosis for people with CVD, mortality rates have nevertheless remained virtually unchanged in the last 20 years [3] [4] [5] . Therefore, there is a need for novel alternative therapies. Embryonic stem cells (ESCs) are pluripotent and are able to differentiate into progenitors; they have the potential to regenerate vascular cells and to replace damaged tissues [6] [7] [8] .
After more than a decade of research with human and mouse ESCs, there is an increasing recognition of the need for nonhuman primate models for stem cell research and applications [9] [10] [11] [12] [13] . With regard to cell-based therapy, stem cell turnover is remarkably higher in small animals than in large ones [14] . That could cause fundamental differences in the stemness profile of therapeutic agents and in the signaling pathways that regulate the fate of ESCs [13] . In addition, the modes of stem cell delivery (dosage, time points, methods) have a profound effect on the efficacy of treatment. Applying the methods for stem cell delivery and treatment developed in small animal models to human subjects is usually problematic [15, 16] . There is also a lack of thorough documentation, especially in a biologically relevant animal model, of cell migration and trafficking to nontarget site(s) and uncontrolled cell proliferation when derived cells are transplanted into subjects. More recently, there has been an increasing awareness that the potency of ESC-derived cells must improve to reach their therapeutic efficacy because we still have not recognized those stem cell derivatives that exert reparative functions like their counterparts as mobilized by the physical insults [17, 18] . Given the similarities between humans and baboons, ESC-derivatives developed from the baboon can be more informative to us about the biology of stem cells in human beings, which facilitates the use of stem cells for clinical applications and optimizes therapies before they are advanced to human clinical studies.
This investigation develops a new approach for generating angioblasts for stem cell therapy and tests the functional competence of endothelium produced from ESCs. We have also established a novel bioassay that allows us to evaluate whether ESC-derived angioblasts have therapeutic effects. The mechanisms underlying this bioassay are based on the fact that microenvironments are vital elements that regulate and promote stem cell differentiation and functioning [19] [20] [21] [22] [23] [24] [25] ; therapeutic cells cannot be identified based solely on their phenotypic markers, but must depend, in part, on their interactions with correct residing environments. Since we seed ESC-derived cells directly in targeted tissue, it enables us to observe direct interactions between candidate-derived cells and their target-damaged tissues; consequently, we can determine what characteristics and which maturation stage give rise to the higher reparative function.
Our results suggest that this approach provides a novel method to validate whether differentiated cells are able to integrate into adult tissue and to function as cell agents. ESCbased therapy has great potential for clinical applications, but optimal clinical benefit cannot be achieved without a good understanding of which cells should be transplanted. Our model can be an important bridge to bringing regenerative medicine a step closer from bench to bedside.
Materials and Methods

Cell culture
Fully characterized baboon ESCs were obtained from the Pittsburgh Development Center, University of Pittsburgh School of Medicine [15, 26, 27] . The BAB15 baboon ESC line at passage 39 was used in this study. They were cultured according to the published method and used within no more than 10 passages [28] . Undifferentiated ESCs were maintained with feeder cells in the ESC medium containing 15% knockout serum replacement; 1% nonessential amino acids (100 · ); 1% l-glutamine (100 · ); 1% antibiotic-antimycotic (100 · ); 100 mM b-mercaptoethanol; and 12 ng/mL human basic fibroblast growth factor (FGF) in knockout Dulbecco modified Eagle's minimal essential medium (DMEM). Endothelial cells (ECs) from an adult blood vessel were isolated and cultured according to the method described previously as a reference control [29] .
In vitro differentiation
Our protocol for differentiating angioblasts from ESCs was modified based on reported methods [30] [31] [32] [33] . We derived angioblasts from ESCs in 3-dimensional embryoid body (EB) culture in the angioblast differentiation medium (ADM). We used AggreWell plates to form uniform EBs containing about 5,000-10,000 cells and cultured them in the ESC medium for 3 days. The ADM consisted of the ESC medium supplemented with a cocktail of 0.5 ng/mL BMP-4, 5 ng/mL basic FGF, 10 ng/mL vascular endothelial growth factor (VEGF), 5 ng/mL stem cell factor, 5 ng/mL thrombopoietin, and 10 ng/mL FLT-3 ligand. Subsequently, we added ADM to EB cultures at gradually increased ratios at the time points indicated in Fig. 1 . All cell cultures were fed with a fresh medium every day during the differentiation process. Samples were taken during EB culture for gene expression profiling and flow cytometry. At the end of day 9, EBs were transferred and cultured on collagen-coated plates for monolayer culture by the modified ADM, in which knockout serum replacement was replaced with an equal amount of fetal calf serum. We harvested specified angioblasts by enzymatic digestion after 12 days in culture to test their reconstitutive ability.
Gene expression by real-time polymerase chain reaction
Total RNA was extracted from EC control cells, and undifferentiated ESCs, and differentiated cells at days 5 and 9 using the RNeasy Plus Mini Kit. The probes used for real time-polymerase chain reaction (RT-PCR) are listed in Table  1 . Quantitative RT-PCR was performed in 25 mL of reaction mix containing 1 · SYBR Ò Green PCR master mix and 200 nM each of forward and reverse primers, template cDNA, and a housekeeping gene (GAPDH) as an internal control; then stopped at 40 cycles (temperature program: 2 min at 50°C, 10 min at 95°C, 40 cycles of 15 s each at 95°C, 1 min at 60°C). Transcripts were amplified on a 7900HT PCR System. Results were expressed by cycle threshold (Ct) values. Three independent experiments were conducted.
Flow cytometry
Single-cell suspensions from EBs were prepared by 1:1 trypsin:collagenase digestion for 30 min. After the cells were washed with cold phosphate-buffered saline (PBS) and blocked by 1% human AB serum in PBS, they were stained with fluorescently conjugated antibodies for flow cytometry at 4°C for 20-30 min. Table 2 lists vendors, clones, and antibody dilutions. UEA-1 conjugated with fluorescein isothiocyanate (Sigma) was used at 5 mL/10 6 cells. Undifferentiated ESCs served as controls for monitoring angioblast differentiation. Isotype-matched control antibody staining was performed using the same cells to determine background fluorescence and for data processing. Flow cytometry was performed on a Cyan (Dako). All flow cytometry procedures were repeated at least 3 times.
Long-term tracing of labeled cells
To trace the transplanted cells in ex vivo culture, we labeled the cells with the fluorescent CellTracker probe, CMRA (Invitrogen), according to the manufacturer's instructions, by replacing the culture medium with a fresh medium (containing 10 mM of CMRA) and incubating for 45 min. Figure 4 shows the prototype of the ex vivo system that was established in our laboratory. The bioreactor has 2 parts: a rotary cylinder [ Fig. 4A(a) ] with 4 stainless steel tubes on both sides [ Fig. 4A(b) ], and a laminar perfusion system driven [ Fig. 4A(c) ] by a digital peristaltic pump. A segment of baboon femoral artery 5-7-cm long and without any branches or holes on the wall was treated with 0.05% trypsin together with 0.1% collagenase and 0.1% DNase I for 30 min at 37°C to remove the endothelium. After thoroughly washing the segment with a medium to detach all ECs, we seeded the transplanted cells onto the lumen of the denuded artery and used plastic tubing to ligate the 2 ends of the vessel segment to the steel tubes in the bioreactor to construct a circuit. The endothelial culture medium (EGM-2, Lonza) in a reservoir [ Fig. 4A(d) ] was perfused through the lumen of the vessel. The whole vessel was submerged in 10% fetal bovine serum F-12K medium and placed in an incubator. Figure 4B is a photograph of ex vivo bioreactor.
Construction of ex vivo bioreactor
In most instances, 2 arterial segments were harvested from the same animal and denuded under the same conditions, then cells were labeled using CellTracker as stated above. The treatment group received a cell suspension (2-5 · 10 5 ) of ESCderived progenitors in 2 mL of the endothelial medium, injected into the lumen of 1 denuded arterial segment; the control group received 2 mL of medium without cells, injected into a second denuded arterial segment from the same baboon. Then, we rotated the rotary cylinder of the bioreactor 90°every hour for 5 h to promote cell attachment to the extracellular matrix. Finally, we perfused the vessel at a lower flow rate of 0.5 mL/min for the first 10 h followed by 2 mL/min for the rest of the culture period to nourish the seeded cells.
Immunofluorescence and whole-mount immunostaining
Cells were seeded on either BioCoat chamber slides or cover slips for immunostaining; single cells from EBs were prepared by 1:1 trypsin/collagenase digestion for 20-30 min at 37°C and cytospun onto the slides. They were fixed in 2% or 4% paraformaldehyde (PFA) in PBS at room temperature for 20 min, then washed twice with 1 mL of PBS for 5 min, and blocked for 45 min with 0.5 mL of 1% bovine serum albumin (BSA), 10% normal donkey serum, and 0.1% Triton X-100 in the Hank's Table 2 ) in 1% BSA and 10% normal donkey serum in the Hank's buffer at 4°C overnight. The next day they were washed in 1% BSA in the Hank's buffer 3 times. The secondary antibody was diluted according to the manufacturer's instructions in 1% BSA in the Hank's buffer, pH 7.2-7.4, for 60 min at room temperature in the dark. Cells were washed 3 times with 1% BSA in the Hank's buffer. Slides were covered with an antifade mounting solution and viewed with a Nikon Eclipse E800 fluorescence microscope. Arterial tissues with and without cell transplantation were embedded in optimal cutting temperature compound (OCT) in a cryomold and overlaid with OCT. The samples were quickly frozen on dry ice; 5-10-mm sections were cut on a superfrost slide and fixed in 2% PFA at room temperature for 20 min. We processed the sections immediately with immunofluorescence staining as described above.
Scanning electron microscopy
Tissue samples were washed 3 times with PBS and immediately fixed in 4% formaldehyde/1% glutaraldehyde for further processing. Images were taken using the LEO 435VP scanning electronic microscope.
Results
In this study, we developed a protocol to generate angioblast cultures from baboon ESCs, characterized their biological features, and evaluated whether they could repair a damaged arterial endothelium by determining the growth of derived angioblasts on a denuded vessel surface. Figure 1 is an outline of our experimental design.
Characteristics of pluripotent baboon ESCs
We evaluated the pluripotency of undifferentiated ESCs based on previously reported methods [15, [26] [27] . Typical ESC colonies were seen after regular passaging with feeder cells (Fig. 2a) . These cells also expressed pluripotency markers, such as nuclear NANOG (Fig. 2b) , nuclear OCT-4 ( Fig. 2c) , and membrane SSEA-4 ( Fig. 2d) and showed positive staining for alkaline phosphatase (Fig. 2e) .
Differentiation of angioblasts from ESCs by EB culture
We differentiated ESCs toward angioblasts in the form of embryonic bodies according to the design shown in Fig. 1 ; we FIG. 1. Experimental design for generating angioblasts from ESCs. Undifferentiated ESCs were cultured with feeder cells under routine conditions. The embryoid body (EB) method was used to generate angioblasts from ESCs. After EBs were formed, they were suspended in ESC/ADM media with varying ratios for indicated times. At the end of angioblast induction, they were transferred to collagen-coated plates to reach confluence. The reconstitutive ability of transferred the EBs onto collagen IV-coated plates at day 9 and cultured in monolayer for 12 days in the presence of angiogenic growth factors; during this period, we documented their growth behaviors morphologically under phase-contrast microscopy, as indicated in Fig. 3A . Figure 3A(a) shows EBs before seeding; 1 day after seeding, we observed that some cells migrated from EBs aggressively, proliferated in the monolayer within 3-5 days, and became confluent after 9 days [ Fig. 3A(be) ]. Angioblasts cultured under such conditions dominantly had a typical cobblestone shape [ Fig. 3A(f, g) ].
FIG. 3. (Continued).
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To investigate the molecular signatures under angioblast differentiation, we profiled the gene expression involved in an angioblast formation as reported previously [34, 35] . First, RNAs were isolated from EB cultures that underwent differentiation for 5 and 9 days under the angioblast induction medium, together with undifferentiated ESCs and ECs as controls. Figure  3B shows the amplification of 10 transcripts in a real-time PCR system. We found that the expression levels of 2 pluripotent transcription factors had strongly decreased during EB culture by day 5 and day 9, as indicated by the higher Ct values. NA-NOG was highly expressed in the undifferentiated ESC state (Ct = 25.4), but its expression was decreased at day 5 (Ct = 31.5) and at day 9 (Ct = 32.7) after induction by ADM culture; similarly, OCT3/4 was highly expressed in ESCs (Ct = 20.2), but became moderately expressed after differentiation for 5 days (Ct = 25.5) and 9 days (Ct = 26.0). Transcription factors that control the formation of angioblasts were upregulated in differentiating EBs. T-brachyury was more highly expressed in differentiating EBs (Ct = 25.6 at day 5; Ct = 26.1 at day 9) than in ESCs (Ct = 32.0); GATA2 showed the same trend in comparing differentiated EBs (Ct = 25.6 at day 5, Ct = 26.1 at day 9) with ESCs (Ct = 34.8). Angioblasts generated by the current protocol did not express mature endothelial proteins, such as CD144, TEK, and VWF. CD34 in differentiating EBs at day 5 (Ct = 32.5) and at day 9 (Ct = 31.0) was slightly increased in comparison to ESC (Ct = 35.5). CD31 expression was the highest after 5 days of differentiation (Ct = 27.6), and its expression was lower after 9 days (Ct = 31.0), similarly to expression of ECs (Ct = 29.5) and ESCs (Ct = 31.6). KDR, another mesodermal marker, showed upregulation in differentiating EBs (day 5 vs. day 9), but high levels were found in both ESCs and ECs. To validate the expression of key molecules that control mesodermal formation, we disassociated cells from ESCs and EBs at day 5 by enzymatic digestion and cytospun them onto slides; we found that GATA2 was strongly stained in EBs at day 5, while T-brachyury was stained strongly in some cells. KRD positivity was stronger in ESCs than differentiating EBs at day 5 (Fig. 3C) .
Second, we investigated cellular surface antigenic expression during the differentiation by flow cytometry analysis. Single cells were prepared from undifferentiated ESCs and from EBs in ADM culture for 3 days and 9 days. We immunostained the cells for CD34, CD31, CD117, CXCR4,
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and VEGFR3. Several populations appeared during the differentiation process as shown in Fig. 3D ; the corresponding positivity in percentage is provided in Table 3 . We found that EB culture for 3 days dramatically promoted CD31 expression [95.96%; Fig. 3D Fig. 3D(h, i) ]. A population with coexpressed CD34 + /CD31 + , but not CD117, appeared at day 9 [1.04%; Fig. 3D(c, f ) ]. These results illustrate that EB culture under ADM resulted in the formation of several populations with angioblast characteristics.
Next, we observed the growth of derived angioblasts and documented their potential to differentiate under static culture conditions. After they were harvested, EBs were transferred to collagen-coated plates and cultured under the modified ADM. One day after culture, we observed that suspended cell clusters coexisted with adherent cells [ Fig.  3E(a) ]. After culture for 7-10 days, we could distinguish 3 distinct types of colonies with different shapes: (1) grapeshaped cell clusters [ Fig. 3E(c) , reddish hemoglobinized cells] under phase-contrast microscopy that stained positively for CD235a [ Fig. 3E(f ), in red] , an erythrocyte precursor marker; (2) spindle-shaped cells [ Fig. 3E(d) ] that stained positively for smooth muscle a-actin with mature fibers in some cells as well as unassembled protein in other cells [ Fig. 3E(g) ], indicating a smooth muscle cell origin; and (3) cobblestoneshaped cells [ Fig. 3E(e) ] that strongly stained for CD34 [ Fig.  3E(h) ], indicative of endothelial-like cells. In addition, we observed multiple lumen and capillary structures spreading out in the culture dishes [ Fig. 3E(b), indicated by red arrows] .
The above data indicated that our angioblast differentiation protocol could generate angioblasts via mesodermal intermediates and that the derived cells demonstrated dual potential to differentiate into hematopoietic and vascular lineages.
Reconstitution of angioblasts derived from ESCs under ex vivo culturing
To test whether derived angioblasts could function as therapeutic agents in a reparative role, we examined their ability to re-endothelialize blood vessels whose endothelium was removed by enzymatic digestion in the ex vivo bioreactor (Fig. 4) . After ex vivo culturing with EGM-2, we took samples of the vessel segment for scanning electron microscopy and immunofluorescence, to assess the fate of the transplanted cells. Figure 5 shows the evidence of the integration of angioblasts cultured under EGM-2 perfusion on denuded vasculature under ex vivo culture. By using scanning electron microscopy, we demonstrated that ESC-derived angioblasts
FIG. 4. Ex vivo bioreactor. (A)
Diagram of bioreactor for evaluating the reconstitutive ability of derived angioblasts. The bioreactor has 2 parts: a rotary cylinder (a) with 4 stainless steel tubes on both sides (b), and a laminar perfusion system (c) driven by a digital peristaltic pump. The cells to be tested were seeded onto the lumen of the denuded artery, and then the 2 ends of the segment were ligated with plastic tubing to construct a circuit. Endothelial differentiation medium in a reservoir (d) was perfused through the lumen of the vessel using a digital peristaltic pump. The vessel was submerged in medium and placed in an incubator. (B) Photograph of the bioreactor. . Finally, we investigated whether transplanted derived angioblasts could functionally reconstitute the damaged endothelium. After ex vivo culturing for approximately 2 weeks, a 0.5-0.7-cm segment was fixed, embedded, and sectioned longitudinally into 10-mm-thick serial sections and whole-mount immunostaining was performed to assess the fate of the transplanted cells. Figure 5B shows cellular images acquired from serial sections from a representative ex vivo sample. Angioblasts labeled with CellTracker (in red) were found to integrate and recover the denuded surface under ex vivo culture; and integrated cells expressed CD31 (in purple) after prolonged culture [ Fig. 5A(d) ] by comparison to short-term 5-day perfusion [ Fig. 5A(c) ]; CD31 is an antigenic marker for ECs lining the lumen of blood vessels. This result indicated that the transplanted ESC-derived angioblasts possessed reparative ability and were able to repair the injured vascular tissue.
Discussion
The development of stem cell-based therapies and their application for regenerative medicine have become more dependent on animal models [36] . Results from those models, whether amphibians or mammals, have contributed to a better understanding of the mechanisms underlying cell therapy. However, large animal models have demonstrated a better suitability for translation to humans, since a substantial body of evidence has clearly demonstrated differences between human and mouse ESCs [37] [38] [39] . A large Old World nonhuman primate, the baboon, has an advantage over other large models because of the high level of similarity of its physiological characteristics to those of humans [13, [40] [41] [42] . The results of the present study suggest that baboon ESCs represent a new research tool that is highly relevant for stem cell therapy in human, thus contributing to developing clinical application of stem cell therapies.
Our results indicate that baboon ESC differentiation toward the endothelial lineage resembles the process in humans. In human ESCs, derivation of endothelial lineage cells appears to undergo the cascade of molecular events leading to the commitment to mesoderm and the formation of hemangioblasts [40] [41] [42] [43] . When baboon ESCs were cultured as EBs in culture with vasculogenic factors (VEGF, FGF, and BMP-4), we observed upregulated expression of mesodermal markers and downregulated pluripotent markers (Fig. 3B,  C) , which are very similar to the results seen with human ESCs. We also observed that angioblasts derived from baboon ESCs by EB formation, a process that partially mimics the spatial organization of cells in embryo, could generate both adherent and nonadherent cells [ Fig. 3E(a) ] under in vitro culturing, and that some adherent colonies expressed endothelial markers [ Fig. 3E(e) ]. This observation is consistent with the results of Zambidis et al., who found that hematopoietic differentiation of human ESCs generated 2 types of colonies at the early stage of differentiation [44] . They described that nonadherent cells expressed CD45 and gave rise to hematopoietic colonies, and that adherent cells differentiated into ECs. We also confirmed that baboon angioblasts generated using the current protocol exhibited markers in a time-dependent manner (Fig. 3D ) that closely recapitulates endothelial differentiation in vivo during embryonic development [45, 46] , and shared common phenotypic characteristics with human ESCs [40, 47, 48] . More interestingly, the kinetics and efficiency of CD34 + /CD31 + cells in baboons were very close to those reported for human ESCs [40, 47, 48] . When angioblast cultures were grown in a monolayer, they have the potential for multiple lineage differentiation. As shown in Fig. 3E(a-h) , baboon angioblast cultures are able to differentiate into hematopoietic and vascular lineages under current conditions; these data were consistent with previous findings that dual potential hemangioblasts exist during human ESC differentiation [33, 48, 49] . Although there were differences in the kinetics of hematopoietic commitment occurrence, both human and baboon ESCs could be derived into multiple cell lineages, depending on the culture conditions. One particular similarity is that both human and baboon undifferentiated ESCs express KDR (Fig. 3B, C) , whereas they expressed CD34 only when they underwent differentiation toward angioblasts [ Fig. 3D(a-c, d-f ) ] [47, 50] . However, we noticed that 2 CD34 + populations were expressed with high or low intensity during baboon ESC differentiation toward ECs, which has not been reported in human ESCs, as shown in Fig. 3D(c, f ) ; further studies are required to determine whether human ESCs, if treated by our established procedure, give rise to the same populations. Collectively, the above findings suggest that the differentiation of baboon ESCs may maximally represent the molecular and cellular events that regulate embryonic EC fate in human stem cells.
We have demonstrated that differentiated baboon ESCs possess reparative function and are able to recover damaged arterial tissues. ECs derived from human ESCs are capable of forming vascular-like structures [50] , having similar gene expression patterns to those of mature ECs [51] , and improving blood circulation [32, 48] . To demonstrate the functionalities of derived cells in the baboon, we tested the endothelium-forming ability of ESC-derived angioblasts in an ex vivo culture system. Since it remains unclear which characteristics are essential for angioblasts to form the endothelium, we transplanted heterogeneous angioblast cultures after they were specified under monolayer conditions, which allowed derived cells grow maximally in ex vivo culture conditions (data not shown). Our data from scanning electron microscopy demonstrated that transplanted ESCderived angioblasts attach to the interior lumen of a denuded blood vessel within 5 days; prolonged culturing allowed the attached cells to integrate the damaged vessel surface and to express the endothelial specific antigen CD31, thus reconstituting the vessel.
Using the baboon as a research model enables us to conduct experiments or manipulations that are impossible to perform in humans. There is increasing evidence that stem cells are capable of differentiating and proliferating if only they reside in their appropriate niches [52, 53] ; the regulation, survival, proliferation, and differentiation of stem cells is ultimately determined by a combination of factors intrinsic to the stem cells themselves and extrinsic signals received from the microenvironment [19] [20] [21] [22] [23] [24] . Organ-specific regulators, other as-yet-unrecongnized factors and matrix components are essential for functional incorporation of transplanted cells [18] . Since our ability to bring pluripotent stem cell biology into cell-based therapy will depend largely on the effectiveness of the derived cells, functional and therapeutic ESC-derived regenerative cells cannot be correctly identified without considering their cellular and molecular interactions with their environmental components. In this study, we designed a novel approach to identify functional and highly regenerative cells for stem cell therapy based on this principle. We placed the committed ESCderived angioblasts in a naturally damaged environment that provides the appropriate combination of their surroundings and allowed them direct contact with signaling molecules to induce and support lineage-specific differentiation, thus facilitating their incorporation and maturation. We confirmed that ESC-derived angioblasts have the potential to replace the endothelium; the baboon is the most suitable model to perform this investigation because of the availability of the biopsy tissues.
While many ESC-derived cells appear to be attractive therapeutic options for treating vascular injury, standard and robust in vitro and in vivo investigations of the biology of these cells are needed to identify those that will be the most amenable to therapeutic application. Using our model system, we can discriminate the potential cell candidates that are able and ready to regenerate the damaged endothelium from those are not, reproducibly. To our knowledge, this is the first objective and controlled system for evaluating the functionalities of ESC-derived cells; it is impractical to assess the therapeutic value of potential candidates in this manner because human arteries are not available for the ex vivo assay system on a day-to-day basis. Although in this study, we used a heterogeneous population to demonstrate their ability to reconstitute damaged blood vessels, we are aware that phenotype-defined cell populations will be required for optimal cell therapy. We plan to use our bioassay system to screen a wide spectrum of purified populations that are derived from undifferentiated cells to determine which cells are 640 SHI ET AL.
optimal therapeutic candidates; we also plan to develop an expansion protocol to induce differentiation of pluripotent stem cells into readily transplantable cells to promote tissue repair, restoration, and regeneration.
In conclusion, we have successfully established a protocol to differentiate baboon ESCs into endothelial lineage cells and confirmed their therapeutic functionalities by a bioassay system in a preclinical setting. With the advent of stem cell processing technology and its application in medicine, generating functional endothelial precursors for rejuvenating blood vessels will form a cornerstone for the prevention and treatment of CVD.
